Intellia Therapeutics, Inc. (NASDAQ:NTLA) Director Sells $14,278.81 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) Director Jesse Goodman sold 1,547 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $9.23, for a total transaction of $14,278.81. Following the sale, the director directly owned 24,359 shares of the company's stock, valued at $224,833.57. The trade was a 5.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Intellia Therapeutics Stock Up 8.6%

Intellia Therapeutics stock traded up $0.85 during mid-day trading on Wednesday, reaching $10.73. 7,226,651 shares of the company's stock traded hands, compared to its average volume of 2,958,305. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18. The stock has a 50 day moving average of $8.62 and a two-hundred day moving average of $9.41. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -2.05 and a beta of 2.21.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.16. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The firm had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. During the same period in the prior year, the company earned ($1.12) EPS. The business's revenue was down 42.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its holdings in Intellia Therapeutics by 2.1% during the 4th quarter. Rhumbline Advisers now owns 166,248 shares of the company's stock valued at $1,938,000 after buying an additional 3,499 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Intellia Therapeutics during the 4th quarter valued at about $304,000. Oppenheimer & Co. Inc. purchased a new stake in Intellia Therapeutics in the 4th quarter worth about $209,000. Jones Financial Companies Lllp lifted its stake in Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after purchasing an additional 2,280 shares during the last quarter. Finally, Aigen Investment Management LP purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at approximately $213,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Canaccord Genuity Group reduced their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Truist Financial reduced their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Chardan Capital restated a "buy" rating and set a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. Citigroup decreased their price target on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $7.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 16th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.37.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.